News & blog

Vet pharmaceuticals firm’s strong first half

International veterinary products company Dechra is trumpeting a strong first-half performance in the six months to December 31.

Revenue including its October 2015 Croatian acquisition Genera was up 14% to £110.7m at constant exchange rate (CER) (2015: 100.9m) while EBITDA was also up 24.6% to £28.7m (2015: £24.8m) at CER.

The growth for the Northwich, Cheshire-based company was helped by growth in EU Pharmaceuticals, including Genera, was encouraging at 8.1% (CER), but it continues to be adversely impacted by exchange rate headwinds with 0.9% growth at actual exchange rate (AER).

Read more